Related references
Note: Only part of the references are listed.Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study
Asher Chanan-Khan et al.
LANCET ONCOLOGY (2016)
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
Andrew W. Roberts et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations
Yi Ling Teo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial
Mohammed Z. H. Farooqui et al.
LANCET ONCOLOGY (2015)
Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia
J. A. Burger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
FDA-approved small-molecule kinase inhibitors
Peng Wu et al.
TRENDS IN PHARMACOLOGICAL SCIENCES (2015)
Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation
S. Kamel et al.
LEUKEMIA (2015)
Effect of CYP3A perpetrators on ibrutinib exposure in healthy participants
Jan de Jong et al.
PHARMACOLOGY RESEARCH & PERSPECTIVES (2015)
Absorption, Metabolism, and Excretion of Oral 14C Radiolabeled Ibrutinib: An Open-Label, Phase I, Single-Dose Study in Healthy Men
Ellen Scheers et al.
DRUG METABOLISM AND DISPOSITION (2015)
Ibrutinib treatment affects collagen and von Willebrand factor-dependent platelet functions
Marie Levade et al.
BLOOD (2014)
Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study
Jan A. Burger et al.
LANCET ONCOLOGY (2014)
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
J. C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
Richard R. Furman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Prevalence of potential drug-drug interactions in cancer patients treated with oral anticancer drugs
R. W. F. van Leeuwen et al.
BRITISH JOURNAL OF CANCER (2013)
Twelve-Month Frequency of Drug-Metabolizing Enzyme and Transporter-Based Drug-Drug Interaction Potential in Patients Receiving Oral Enzyme-Targeted Kinase Inhibitor Antineoplastic Agents
Steven J. Bowlin et al.
MAYO CLINIC PROCEEDINGS (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Impact of clinical pharmacy services on patients in an outpatient chemotherapy academic clinic
Megan McKee et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2011)
Is there a benefit to having a clinical oncology pharmacist on staff at a community oncology clinic?
Aimee Danette Ruder et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2011)
OncoRx-IQ: a tool for quality assessment of online anticancer drug interactions
Kevin Yi-Lwern Yap et al.
INTERNATIONAL JOURNAL FOR QUALITY IN HEALTH CARE (2010)
Drug interactions in oncology: how common are they?
R. P. Riechelmann et al.
ANNALS OF ONCOLOGY (2009)
Drug interactions in cancer therapy
Charity D. Scripture et al.
NATURE REVIEWS CANCER (2006)
Herbal remedies in the United States: Potential adverse interactions with anticancer agents
A Sparreboom et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Interactions of herbs with cytochrome P450
SF Zhou et al.
DRUG METABOLISM REVIEWS (2003)
Share Paper
